Ventyx Biosciences shares drop 20% in premarket after Phase 2a trial of VTX3232 for early Parkinson's disease only met safety and tolerability goals.

Ventyx Biosciences, Inc. plunged 20% in premarket trading after the company announced that its Phase 2a study for VTX3232 in early Parkinson's disease patients only met safety and tolerability primary endpoints, with no efficacy results reported. The company's core competency is focused on the development of NLRP3 inhibitors, and VTX3232, as the core product, requires further Phase 2 trials to prove clinical efficacy.